Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552818 | 0.98 | TAAR1 (0.61) | TAAR1MAOBMIFIDO1ALDH1A1 | |
| SCHEMBL18856960 | 0.89 | TAAR1 (0.57) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL934227 | 0.87 | TAAR1 (0.73) | TAAR1MAOBMIFIDO1ALDH1A1 | |
| SCHEMBL11398638 | 0.85 | TAAR1 (0.53) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL1046741 | 0.83 | TAAR1 (0.61) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL3989285 | 0.82 | TAAR1 (0.54) | TAAR1MAOBMIFIDO1ALDH1A1 | |
| SCHEMBL96238 | 0.82 | TAAR1 (0.54) | TAAR1MAOBMIFIDO1ALDH1A1 | |
| SCHEMBL28862215 | 0.80 | TAAR1 (0.71) | TAAR1MAOBMIFIDO1ALDH1A1 | |
| SCHEMBL1047192 | 0.79 | TAAR1 (0.57) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL398644 | 0.78 | TAAR1 (0.61) | TAAR1MAOBMIFIDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118695626-A | Perovskite solar cell, preparation method thereof and electric equipment | 天合光能股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118695626-A | Perovskite solar cell, preparation method thereof and electric equipment | 天合光能股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-8940900-B2 | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2125735-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | Advinus Therapeutics Private Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008104994-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-09-04 | — | — | WO | disclosed |
| US-20050240034-A1 | Artemisinin-based peroxide compounds as broad spectrum anti-infective agents | MISSISSIPPI, THE UNIVERSITY OF | 2005-10-27 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240034-A1 | Artemisinin-based peroxide compounds as broad spectrum anti-infective agents | CASP10, HCCS, CASP9 | TAAR1 4461/4885MAOB 537/4885MIF 2602/4885 |
| US-20140357685-A1 | Sodium Channel Inhibitors | TRPV1, SCN1A, SCN2A | TAAR1 2101/4885MAOB 2147/4885MIF 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.